Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 17/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | GAK | O14976 | 3/20 | 0.51 |
| ▸ | FBP1 | P09467 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | BUB1 | O43683 | 2/20 | 0.47 |
| ▸ | STK10 | O94804 | 2/20 | 0.47 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.47 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.47 |
| ▸ | CARS1 | P49589 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.47 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922638 | 0.80 | HTT (0.65) | EGFRERBB2ABL1LMNAABL2 | |
| SCHEMBL4913660 | 0.80 | TTBK1 (0.63) | EGFRMAPTERBB2ABL1LCK | |
| SCHEMBL4923317 | 0.80 | EGFR (0.65) | AURKAEGFRFBP1ERBB2ABL1 | |
| SCHEMBL4917994 | 0.80 | MAPK1 (0.58) | EGFRFBP1MAPTABL1LCK | |
| SCHEMBL7014899 | 0.79 | EGFR (0.66) | AURKARPS6KB1EGFRKDRGAK | |
| Hydrochloric Acid SCHEMBL7537154 | 0.78 | TTBK1 (0.61) | EGFRMAPTERBB2ABL1LCK | |
| SCHEMBL891009 | 0.78 | TTBK1 (0.57) | EGFRALDH1A1ERBB2DAPK3ABL1 | |
| Hydrochloric Acid SCHEMBL7016965 | 0.78 | EGFR (0.64) | AURKARPS6KB1EGFRKDRGAK | |
| SCHEMBL7016150 | 0.77 | BRAF (0.58) | AURKARPS6KB1EGFRKDRGAK | |
| SCHEMBL20119339 | 0.76 | EGFR (0.58) | EGFRKDRLMNABRAFSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3290666-B2 | — | — | 2002-06-10 | — | — | JP | claimed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | claimed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | claimed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20230219964-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | SYDDANSK UNIVERSITET (DK) | 2023-07-13 | — | — | US | disclosed |
| WO-2021219813-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | SYDDANSK UNIVERSITET (DK) | 2021-11-04 | — | — | WO | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219964-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | HDAC6, Q6ZSR9, MON2 | AURKA 712/4885RPS6KB1 579/4885EGFR 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.